Korean J Med.
2014 Aug;87(2):224-228. 10.3904/kjm.2014.87.2.224.
Two Cases of Treatment with Intrathecal Rituximab for Primary Central Nervous System Lymphoma
- Affiliations
-
- 1Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea. yjyuh@paik.ac.kr
- 2Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Seoul, Korea.
- KMID: 1710036
- DOI: http://doi.org/10.3904/kjm.2014.87.2.224
Abstract
- Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin's lymphoma (NHL), usually composed of diffuse large B-cells. Although rituximab is known for its curative effect on B-cell NHL, data on the use of intrathecal rituximab for PCNSL are limited. In this report, we present two patients showing relapsed PCNSL with lymphomatous meningitis. Both patients were refractory to conventional methotrexate-based intrathecal chemotherapy. However, after intrathecal rituximab with or without conventional intrathecal chemotherapy, both patients showed stable disease on magnetic resonance brain imaging and cerebrospinal fluid analysis. There were no serious adverse events during each of 3 and 6 cycles with intrathecal rituximab immunotherapy.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of the Cauda Equina Syndrome Associated With the Intrathecal Chemotherapy in a Patient With Primary Central Nervous System Lymphoma
- Recent advances in the management of primary central nervous system lymphoma
- Primary Central Nervous System Lymphoma Mimicking Behcet's Disease
- Advances in the treatment of newly diagnosed primary central nervous system lymphomas
- Combination Therapy with Rituximab and Temozolomide for Recurrent and Refractory Primary Central Nervous System Lymphoma
